iRhythm Holdings (IRTC) Aktievy
iRhythm Holdings, Inc. är ett digitalt hälsovårdsföretag som bedriver design, utveckling och kommersialisering av enhetsbaserad teknik som tillhandahåller ambulatoriska hjärtövervakningstjänster för att diagnostisera arytmier i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 3/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
IRTC Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
iRhythm Holdings, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$113.26 |
| 52 veckors högsta | US$212.00 |
| 52 veckors lägsta | US$100.85 |
| Beta | 1.27 |
| 1 månads förändring | -0.44% |
| 3 månaders förändring | -7.63% |
| 1 års förändring | -17.33% |
| 3 års förändring | 10.57% |
| 5 års förändring | 115.28% |
| Förändring sedan börsintroduktionen | 334.78% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jul 06
IRTC: Reimbursement Policy Shift Will Reshape Earnings Power And Sentiment
For iRhythm Holdings, the analyst fair value estimate has shifted from about $254 to roughly $229, as analysts recalibrated models in light of corrected EPS forecasts and a broader reset in medtech valuation assumptions. Analyst Commentary Recent Street research around iRhythm Holdings shows a mix of recalibrated models and shifting price targets, as analysts factor in updated EPS calculations and a reset in medtech valuation assumptions.
Uppdatering av berättelse • Jun 22
IRTC: Medtech Repricing And EPS Reset Will Support Future Upside Potential
Analysts have trimmed their price targets on iRhythm Holdings, with one moving from $180 to $152 and another from $225 to $180, citing updated EPS modeling and a reset of medtech valuations in light of sector wide concerns around product cycles, the Affordable Care Act and utilization trends, inflation, and capital flowing to data centers rather than healthcare. Analyst Commentary Recent research on iRhythm Holdings points to a mixed but engaged view from Wall Street, with valuation tweaks tied to detailed EPS modeling and sector wide medtech repricing rather than a simple change in stance on the underlying business.Uppdatering av berättelse • Jun 06
IRTC: Medtech Reset And EPS Revisions Will Set Up Future Upside
Analysts have trimmed the iRhythm Holdings fair value estimate from $195.00 to about $178.93, reflecting a series of reduced Street price targets as models are updated for lower projected EPS and a reset in medtech valuations. Analyst Commentary Recent Street research on iRhythm Holdings shows a mix of optimism on the companys long term potential and caution around execution risks and sector level valuation resets.Recent updates
Uppdatering av berättelse • Jul 06
IRTC: Reimbursement Policy Shift Will Reshape Earnings Power And Sentiment
For iRhythm Holdings, the analyst fair value estimate has shifted from about $254 to roughly $229, as analysts recalibrated models in light of corrected EPS forecasts and a broader reset in medtech valuation assumptions. Analyst Commentary Recent Street research around iRhythm Holdings shows a mix of recalibrated models and shifting price targets, as analysts factor in updated EPS calculations and a reset in medtech valuation assumptions.Uppdatering av berättelse • Jun 22
IRTC: Medtech Repricing And EPS Reset Will Support Future Upside Potential
Analysts have trimmed their price targets on iRhythm Holdings, with one moving from $180 to $152 and another from $225 to $180, citing updated EPS modeling and a reset of medtech valuations in light of sector wide concerns around product cycles, the Affordable Care Act and utilization trends, inflation, and capital flowing to data centers rather than healthcare. Analyst Commentary Recent research on iRhythm Holdings points to a mixed but engaged view from Wall Street, with valuation tweaks tied to detailed EPS modeling and sector wide medtech repricing rather than a simple change in stance on the underlying business.Uppdatering av berättelse • Jun 06
IRTC: Medtech Reset And EPS Revisions Will Set Up Future Upside
Analysts have trimmed the iRhythm Holdings fair value estimate from $195.00 to about $178.93, reflecting a series of reduced Street price targets as models are updated for lower projected EPS and a reset in medtech valuations. Analyst Commentary Recent Street research on iRhythm Holdings shows a mix of optimism on the companys long term potential and caution around execution risks and sector level valuation resets.Uppdatering av berättelse • Apr 30
IRTC: 2026 Guidance And DOJ Overhang Weakness Will Support Future Upside
Analysts have trimmed the blended fair value estimate for iRhythm Holdings by about $4.57 to $195.00. This reflects a series of recent price target reductions across the Street that center on sector wide multiple compression following Q4 updates and ongoing DOJ related headline risk.Ny berättelse • Apr 23
Long Term Cardiac Monitoring And AI Will Transform This Ambulatory Heart Care Leader
Catalysts About iRhythm Holdings iRhythm Holdings provides ambulatory cardiac monitoring services using wearable biosensors, AI tools and integrated clinical workflows. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Apr 15
IRTC: 2026 Guidance And DOJ Overhang Weakness Will Drive Future Upside
Analysts have reduced their average price targets on iRhythm Holdings by about $12. This reflects slightly higher discount rate assumptions, modestly lower revenue growth expectations, and a lower future P/E multiple, even as longer term profit margin assumptions have increased.
Ny berättelse • Apr 08
Primary Care And AI Headwinds Will Challenge Cardiac Monitoring Expansion Yet Ultimately Support Progress
Catalysts About iRhythm Holdings iRhythm Holdings provides ambulatory cardiac monitoring services built around its Zio biosensor platform and related analytics. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Mar 31
IRTC: 2026 Guidance And DOJ Overhang Weakness Will Support Future Upside
iRhythm Holdings' updated fair value estimate edges up to about $211.43 per share, as analysts trim Street price targets into a tighter $184 to $225 range, citing sector wide multiple compression alongside Q4 execution and reiterated long term guidance. Analyst Commentary Research desks are consolidating around a tighter fair value band for iRhythm, with most recent moves involving modest price target trims that still sit above current Street lows.Uppdatering av berättelse • Mar 16
IRTC: 2026 Guidance And Sector Reset Will Support Future Upside
iRhythm Holdings’ updated analyst price target of $211, slightly below the prior fair value estimate of about $212.87, reflects analysts fine tuning assumptions on discount rate, profit margins and future P/E multiples following recent sector wide target resets and mixed, yet generally supportive, research commentary on the company’s growth profile. Analyst Commentary Recent research on iRhythm Holdings shows a cluster of target price revisions, with most firms trimming their numbers but generally maintaining positive or neutral ratings.Uppdatering av berättelse • Mar 02
IRTC: 2025 And 2026 Guidance Resilience Will Support Future Upside
Analysts have trimmed their average price target for iRhythm Holdings to about $213 from roughly $221 as they factor in lower valuation multiples across peers, while still highlighting recent revenue execution and margin improvement. Analyst Commentary Recent research on iRhythm shows a mix of optimism around execution and growth alongside a reset in valuation expectations, with several firms trimming price targets even as they acknowledge operational progress.Uppdatering av berättelse • Feb 16
IRTC: 2025 Revenue Update And 2026 Outlook Will Support Future Upside
Analysts have nudged their price targets on iRhythm Holdings higher, with updates such as Wells Fargo moving to $225 from $220 and Goldman Sachs to $211 from $202. They cited the company’s 2025 revenue update above prior guidance and a 2026 growth outlook of 17% to 18% as key supports.Uppdatering av berättelse • Feb 02
IRTC: 2025 Outlook And 2026 Expansion Will Support Future Market Share Gains
Analysts have raised their average price target for iRhythm by about $1, to roughly $221, citing the company's pre-announced 2025 revenue outlook above prior guidance and a 2026 revenue growth outlook of 17% to 18% as key supports for the updated view. Analyst Commentary Recent research on iRhythm points to a mix of optimism and caution, with price targets adjusted around the company’s updated 2025 and 2026 revenue outlook.Seeking Alpha • Jan 31
iRhythm: Structural Shift To Profitable Growth
Summary iRhythm is transitioning from speculative growth to a quality compounder, driven by operating leverage, expanding indications, and international growth. IRTC forecasts 2025 revenue over $740M and 2026 revenue of $870M-$880M, with adjusted EBITDA margin rising to 11.5%-12.5%. Penetration into primary care, expansion into sleep apnea and chronic disease markets, and international scaling underpin a robust, sustainable growth thesis. Despite valuation premium and execution risks, I see IRTC’s positive free cash flow and margin expansion as justifying a bullish stance. Read the full article on Seeking AlphaUppdatering av berättelse • Jan 19
IRTC: Future Core Business Momentum Will Support Cardiac Monitoring Market Share Gains
Analysts have nudged their fair value estimate for iRhythm to $220.60 from $218.60, tying the modest move higher to higher modeled revenue growth, slightly different profit margin assumptions, and updated P/E expectations following recent price target increases from several firms and the company’s revised 2025 and 2026 revenue outlook. Analyst Commentary Street research on iRhythm has recently focused on updated revenue outlooks for 2025 and 2026 and how those feed into valuation frameworks and price targets.Uppdatering av berättelse • Jan 04
IRTC: Future Core Business Momentum Will Drive Cardiac Monitoring Market Share Expansion
Analysts have nudged their blended fair value estimate for iRhythm Technologies modestly lower by about $2 to roughly $219, even as they lift published price targets into the low $200s. They cite a clean Q3 beat and raise, accelerating Zio AT adoption, and growing confidence in the durability of the company’s long term cardiac monitoring growth story.Uppdatering av berättelse • Dec 15
IRTC: Future Core Business Momentum Will Drive Stronger Market Share Expansion
Analysts nudged their average price target on iRhythm Technologies slightly higher to about $221 from roughly $220, citing consistent beat and raise quarters, stronger than expected Q3 results, and growing confidence in the long term growth trajectory of the Zio cardiac monitoring portfolio. Analyst Commentary Street research remains firmly constructive on iRhythm Technologies, with recent notes highlighting both accelerating fundamentals and a still demanding valuation backdrop.Uppdatering av berättelse • Nov 29
IRTC: Future Core Business Momentum Will Drive Stronger Market Share Gains
iRhythm Technologies' analyst price target was recently raised from $205 to $230, with analysts citing strong core business performance and increased confidence in the company's growth trajectory following a robust Q3 and elevated FY25 guidance. Analyst Commentary Recent analyst commentary highlights notable optimism around iRhythm Technologies’ execution and future prospects, but also flags several considerations that may temper enthusiasm.Uppdatering av berättelse • Nov 15
IRTC: Future Channel Partnerships Will Drive Continued Market Share Gains
Analysts have raised their price target for iRhythm Technologies from approximately $193 to nearly $220 per share. They cite continued core business strength, expanding Zio AT adoption, and management’s increased confidence in future growth as key factors.Analysartikel • Nov 02
US$220 - That's What Analysts Think iRhythm Technologies, Inc. (NASDAQ:IRTC) Is Worth After These Results
iRhythm Technologies, Inc. ( NASDAQ:IRTC ) investors will be delighted, with the company turning in some strong numbers...Uppdatering av berättelse • Oct 31
IRTC: Future Performance Will Reflect Both Product Momentum And Regulatory Uncertainty
Analysts have raised their price target for iRhythm Technologies from $180 to $205 per share. They cite strong recent results, expanding market share, and a positive outlook for the company's Zio Monitor platform as reasons for the increase.Uppdatering av berättelse • Oct 17
Population Health And EHR Integration Will Redefine Remote Cardiac Care
iRhythm Technologies' analyst price target has increased from $186 to approximately $193. Analysts point to healthy revenue growth, expanded market reach, and positive physician feedback as drivers behind the upward revision.Uppdatering av berättelse • Oct 03
Population Health And EHR Integration Will Redefine Remote Cardiac Care
The consensus analyst price target for iRhythm Technologies has increased modestly from $182.62 to $186.00. Analysts cite positive physician feedback and expected market expansion as key drivers for their outlook.Analysartikel • Aug 27
After Leaping 25% iRhythm Technologies, Inc. (NASDAQ:IRTC) Shares Are Not Flying Under The Radar
iRhythm Technologies, Inc. ( NASDAQ:IRTC ) shares have had a really impressive month, gaining 25% after a shaky period...Uppdatering av berättelse • Aug 27
Population Health And EHR Integration Will Redefine Remote Cardiac Care
The consensus analyst price target for iRhythm Technologies has increased to $181.62, driven by a proposed CMS reimbursement boost, robust MyZio app growth, management’s confidence in market share gains, and progress on FDA remediation, reflecting improved fundamentals and growth visibility. Analyst Commentary Proposed CMS Physician Fee Schedule includes a low-single digit reimbursement boost for mobile cardiac telemetry, reversing previous larger cuts and providing greater payment visibility.Analysartikel • Aug 04
iRhythm Technologies, Inc. (NASDAQ:IRTC) Just Reported And Analysts Have Been Lifting Their Price Targets
A week ago, iRhythm Technologies, Inc. ( NASDAQ:IRTC ) came out with a strong set of second-quarter numbers that could...Analysartikel • Jul 21
Would iRhythm Technologies (NASDAQ:IRTC) Be Better Off With Less Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Ny berättelse • May 26
Ambulatory Monitoring And Digital Health Will Transform Global Markets
Accelerated global adoption of Zio and digital health integration is expanding iRhythm's market reach, operational efficiency, and recurring revenue streams.Analysartikel • Apr 24
iRhythm Technologies, Inc.'s (NASDAQ:IRTC) Share Price Matching Investor Opinion
When you see that almost half of the companies in the Medical Equipment industry in the United States have...Analysartikel • Apr 03
Would iRhythm Technologies (NASDAQ:IRTC) Be Better Off With Less Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysartikel • Feb 15
A Look At The Fair Value Of iRhythm Technologies, Inc. (NASDAQ:IRTC)
Key Insights iRhythm Technologies' estimated fair value is US$112 based on 2 Stage Free Cash Flow to Equity With US$112...Analysartikel • Jan 31
Is It Too Late To Consider Buying iRhythm Technologies, Inc. (NASDAQ:IRTC)?
While iRhythm Technologies, Inc. ( NASDAQ:IRTC ) might not have the largest market cap around , it saw a significant...Analysartikel • Jan 16
What You Can Learn From iRhythm Technologies, Inc.'s (NASDAQ:IRTC) P/S
You may think that with a price-to-sales (or "P/S") ratio of 5.8x iRhythm Technologies, Inc. ( NASDAQ:IRTC ) is a stock...Seeking Alpha • Oct 22
iRhythm Technologies: Today's 510(K) Victory May Only Be A Temporary Reprieve
Summary iRhythm's stock surged over 20% today after the FDA cleared its 510(k) submission for the Zio AT device, despite ongoing regulatory challenges. The company still faces significant hurdles, including a second 510(k) submission, FDA observations, and a DOJ subpoena, impacting its regulatory compliance and reputation. Financial performance remains a concern with projected 2024 revenues of $580-$590 million and no expected profits, questioning the long-term viability of the stock. Despite a potential contrarian trade opportunity, I remain cautious due to unresolved regulatory issues and insufficient revenue generation from iRhythm's products. Read the full article on Seeking AlphaAktieägarnas avkastning
| IRTC | US Medical Equipment | US Marknad | |
|---|---|---|---|
| 7D | -9.6% | -6.0% | 0.2% |
| 1Y | -17.3% | -21.7% | 19.6% |
Avkastning vs industri: IRTC översteg US Medical Equipment branschen som gav -21.7 % under det senaste året.
Avkastning vs Marknaden: IRTC presterade sämre än US marknaden som gav 19.6 % under det senaste året.
Prisvolatilitet
| IRTC volatility | |
|---|---|
| IRTC Average Weekly Movement | 6.8% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: IRTC har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: IRTC s veckovolatilitet ( 7% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2006 | 2,400 | Quentin Blackford | www.irhythmtech.com |
iRhythm Holdings, Inc. är ett digitalt hälsovårdsföretag som bedriver design, utveckling och kommersialisering av enhetsbaserad teknik som tillhandahåller ambulatoriska hjärtövervakningstjänster för att diagnostisera arytmier i USA. Företaget erbjuder Zio ambulatoriska hjärtövervakningstjänster, inklusive långsiktig och kortsiktig kontinuerlig övervakning och mobila hjärtövervakningstjänster med telemetri. Företaget tillhandahåller också Zio Monitor System, ett receptbelagt system för fjärrövervakning av elektrokardiogram (EKG) som består av en EKG-monitor i form av ett plåster som registrerar den elektriska signalen från hjärtat kontinuerligt i upp till 14 dagar; Zio XT System, ett receptbelagt system för fjärrövervakning av EKG som består av Zio XT-plåstret som registrerar den elektriska signalen från hjärtat kontinuerligt i upp till 14 dagar; och Zio ECG Utilization Software System, som stöder insamling och analys av EKG-data.
iRhythm Holdings, Inc. Sammanfattning av grunderna
| IRTC grundläggande statistik | |
|---|---|
| Börsvärde | US$3.70b |
| Vinst(TTM) | -US$27.78m |
| Intäkter(TTM) | US$787.85m |
4.7x
P/S-förhållande-134.0x
P/E-förhållandeÄr IRTC övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| IRTC resultaträkning (TTM) | |
|---|---|
| Intäkter | US$787.85m |
| Kostnad för intäkter | US$228.46m |
| Bruttovinst | US$559.39m |
| Övriga kostnader | US$587.17m |
| Intäkter | -US$27.78m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.85 |
| Bruttomarginal | 71.00% |
| Nettovinstmarginal | -3.53% |
| Skuld/egenkapitalförhållande | 403.4% |
Hur har IRTC utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/15 01:35 |
| Aktiekurs vid dagens slut | 2026/07/15 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
iRhythm Holdings, Inc. bevakas av 25 analytiker. 15 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| David Rescott | Baird |
| Joanne Wuensch | BMO Capital Markets Equity Research |
| Stephanie Elghazi | BofA Global Research |